Jun 04, 2020
  • Sandoz is first and only company offering complete range of dosing options in several European markets*, with 2 mg capsule allowing for fine dose titration
  • Sandoz 2 mg slow-release capsule offers simplified once-daily treatment protocol that may reduce a patient’s daily pill burden1
  • Launch builds on Sandoz experience with Adoport® -- #1 twice-daily generic tacrolimus in Europe2

Holzkirchen, June 4, 2020 – Sandoz today announced the launch of once-daily generic tacrolimus capsules known as Dailiport® in Germany, the UK, Netherlands, Finland, Sweden, Estonia, Latvia, Slovakia and as Conferoport® in Italy and Spain.

Dailiport® / Conferoport® is also expected to be launched soon in other European countries, subject to relevant marketing authorizations being granted, as Sandoz continues to pioneer patient access to critical medicines. Dailiport® / Conferoport® is indicated for use in adult kidney and liver transplant patients and is available in 0.5 mg, 1 mg, 3 mg and 5 mg. The 2 mg dose will also be available in several European countries*.

“Together, Sandoz and Novartis offer the broadest range of transplant medications in the industry,” said Richard Saynor, CEO of Sandoz. “With over 40 years’ experience in transplant care, we continually invest in new and innovative solutions to drive access.  Dailiport® builds on our already extensive expertise in this field with Adoport®, the most widely used generic tacrolimus in Europe.”

Subodh Deshmukh, Head of Sandoz Global Product Development, added: “We are proud of the proven Sandoz technology within this product, thanks to which patients can maintain the optimum dosing level that is so critical in transplant care.”

In the EU, liver and kidney transplants account for the majority of all organ transplant procedures. In 2018, 34,000 organ transplants took place in the EU, of which 21,227 (62%) were kidney and 7,940 (23%) were liver transplants3.

Sandoz medicines, including a broad portfolio of approximately 1000 generics, were used to treat more than 500 million patients in over 100 countries last year4. Sandoz is the #1 provider of generic transplant medications in Europe5 and its predecessor company was the pioneer behind the immunosuppressant cyclosporine discovered in the 1970s by Sandoz scientists6.

About Tacrolimus
Tacrolimus is indicated for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and for the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients7. Tacrolimus should only be prescribed, and changes in immunosuppressive therapy initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients7.

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical need. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2019 sales of USD 9.7 billion. Sandoz headquarters are in Holzkirchen, in Germany's Greater Munich area.

Sandoz is on Twitter. Sign up to follow @Sandoz global at https://twitter.com/Sandoz_Global.

# # #


Novartis Media Relations
Central media line: +41 61 324 2200
Email: [email protected]

Antonio Ligi
Novartis Global Media Relations
[email protected]

Chris Lewis
Sandoz Global Communications
+49 174 244 9501 (mobile)
[email protected]

Katja Minak
Sandoz Global Communications
+49 173 532 6893 (mobile)
[email protected]


  1. Data on file: Dailiport pill burden – UK/MKT/TAC/19-0028.
  2. IQVIA Midas MAT 02 2020
  3. European Commission. https://ec.europa.eu/health/blood_tissues_organs/organs_en [last accessed March 2020]
  4. #1 in Gx market based on volume data by market research company IQVIA through December 2019
  5. IQVIA Midas, Feb 2020
  6. The discovery and development of cyclosporine (Sandimmune). J. F. Borel, Z. L. Kis, T. Beveridge Transplant Proc. 1991 April 23 (2):1867-74.
  7. Dailiport SMPC https://www.medicines.org.uk/emc/product/11029/smpc

*Germany, UK, Netherlands, Sweden, Finland, and Spain


This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.